Ilanga Pharma uye wabonisa idatha kwi-ODOMZO® (iyeza lokunyanga umhlaza wesikhumba) kunye ne-LEVULAN® KERASTICK® + BLU-U®, (yokunyanga izilonda ze-precancerous) ezixhasa ukhuseleko kunye nokusebenza kakuhle.
I-ODOMZO®
ODOMZO® (i-Sonidegib) yamkelwa yi-FDA ngoJulayi 2015. Oku kwafunyanwa ngu ilanga Pharma ukusuka eNovartis ngoDec 2016 kwi $175 yezigidi zentlawulo yangaphambili kunye neentlawulo ezibalulekileyo.
Ngummiselo kagqirha iyeza ithathwe ngomlomo ngohlobo lwecwecwe lokunyanga i-basal cell carcinoma, ethe yavela kwakhona emva kotyando okanye ngemitha okanye engakwazi ukunyangwa ngotyando okanye ngemitha. Esi sisithinteli sendlela yokubonisa iHedgehog. Indlela yeHedgehog (Hh) iyasebenza ngexesha lophuhliso lwe-embryogenic kwaye iyimfuneko yokwahlula iiseli, i-tissue polarity, kunye nokugcinwa kwe-stem cell. Le ndlela ithule kwizicubu zabantu abadala phantsi kweemeko eziqhelekileyo ze-physiological, nangona kunjalo, i-activation ye-Hh engabonakaliyo iye yabandakanyeka ekuphuhliseni nasekukhuthazeni iintlobo ezithile. umhlaza, kubandakanywa ne-basal cell carcinoma (BCC), i-medulloblastoma, kunye nesisu i cancer. I-Basal cell carcinoma kunye ne-squamous cell carcinoma zezona ntlobo zixhaphakileyo ze-nonmelanoma umhlaza wolusu kwaye ichaphazela abantu baseMelika abangaphezu kwezigidi ezithathu ngonyaka.
Ulingo lwekliniki lwe-BOLT lwe-Odomzo, i-double-blind blind, i-randomized, i-controlled, i-42-inyanga ye-200 iphonononga i-ODOMZO 230 mg imihla ngemihla kwizigulane ze-2 ezine-basal cell carcinoma (laBCC) kunye ne-metastatic basal cell carcinoma (mBCC). Amazinga okusinda eminyaka emi-93.2 afunyenwe engama-69.3% (laBCC) kunye nama-XNUMX% (mBCC). Iyeza lanyanyezelwa ngokukhuselekileyo.
LEVULAN® KERASTICK® + BLU-U®
Olu lunyango lwe-photodynamic kuphela precancerous ulusu izilonda ezivunywe yi-FDA (ngoJulayi 1999) ukuze zisetyenziswe kwiindawo eziphezulu ukunyanga 'ubuncinane ukuya kwimodareyitha' iikeratosi ezishinyeneyo zeactinic zobuso, isikhumba sentloko okanye phezulu. Zezi precancerous ukukhula kolusu olunokuthi, ukuba alunyangwa, luguquke lube yi-squamous cell carcinoma. Ngelixa kuphela malunga ne-10 ekhulwini le-actinic keratoses iba nomhlaza, uninzi lweemeko ze-squamous cell carcinoma ziqala njenge-actinic keratosis.
LEVULAN KERASTICK Isisombululo se-20% se-topical, kunye nokukhanyisa ukukhanya okuluhlaza okwesibhakabhaka kusetyenziselwa ukunyanga izilonda. Emva kokuba isisombululo se-LEVULAN KERASTICK sisetyenzisiwe, indawo yonyango iba yi-photosensitive kwaye izigulana kufuneka zikuphephe ukuvezwa kweendawo zonyango ezithatha ifotosensitive. ilanga okanye ukukhanya okuqaqambileyo okungaphakathi (umzekelo, izibane zeemviwo, izibane zegumbi lokutyanda, iibhedi zokusukwa, okanye izibane ezikufutshane) iiyure ezingama-40.
Kwiimvavanyo zeklinikhi, kukho ukukhutshwa okukhulu kwezilonda (80.6%) kwizigulane eziphathwe ngolu nyango xa kuthelekiswa ne-placebo (45.5%). Ukongeza, bekukho ukucaciswa okukhulu kwendawo enkulu yesifo kwi-80% yezigulane ezithatha olu nyango xa kuthelekiswa ne-40% ye-placebo. Unyango lwalunyanyezelwe kakuhle kungekho ngxelo yeziganeko ezimbi kakhulu zeklinikhi.
***
